Sunshine Biopharma says study shows MR1-114 SARS-CoV-2 inhibitor effective in mice, potent in vitro across variants

Sunshine Biopharma Incorporated

Sunshine Biopharma Incorporated

SBFM

0.00
  • Sunshine Biopharma reported publication of Journal of Medicinal Chemistry data on PLpro inhibitor MR1-114 targeting SARS-CoV-2.
  • Study showed nanomolar in vitro potency across variants; oral dosing reduced viral replication in a SARS-CoV-2 mouse model.
  • Mouse efficacy was described as comparable to nirmatrelvir in Paxlovid, supporting potential clinical development for SARS coronavirus infections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.